The drug, which would be marketed under the name Effient, will be up for review by the FDA in September, Eli Lilly said Monday. "We remain confident in our prasugrel submission package," said Dr. Jennifer Stotka, vice president for Global Regulatory Affairs at Lilly.

Prasugrel is being co-developed by Daiichi Sankyo Co. in Japan and Indianapolis-based Eli Lilly as a potential treatment for patients with acute coronary syndromes.